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ABSTRACT 
 
Objectives 
 To identify the adverse events and classify the observed event and its management 
Incidence of adverse event after vaccination and type of reaction for different adverse event. 
 Some question, is there in knowledge about the immunization in parents. 
Methods 
It was a prospective, observational study that included patients of either sex, under the 
age of five in the pediatric wards of a tertiary care hospital. Study patients were followed 
throughout their outpatient department. Whenever an adverse event was detected, all the required 
data were collected and analyzed. Data was analyzed for incidence and after classifying the 
WHO guidelines. 
Results 
Of the 183 children population collected data and enrolled in the study.A total of 33 
adverse events was identified from 33 children. The incidence of adverse event was 18%. Female 
patients experienced majority (58%) of adverse events. The drug most commonly implicated in 
adverse event to prescribed paracetamol syrup. Among the adverse events reported, 18% of 
adverse events were mild. Out of 183 parents, 77% (n=140) of parents are saying yes, vaccines 
are important and 18% (n=33) of parents said don’t know, only 5% (n=10) of parents said it was 
not important. 
Conclusions 
Among the pediatric population, infants, female gender and those receiving a medication 
are at risk of developing adverse event. Parents are had good knowledge regarding 
immunization.  Constant monitoring is required to address the safety issue of the pediatric 
population, especially in infants. So most of the infant, pediatric vaccines are safety. 
  
 
 
 
 INTRODUCTION 
The goal of immunization is to protect the individual and the public from vaccine 
preventable diseases. Although modern vaccines are safe, no vaccine is entirely without risk. 
Some people experience events after immunization ranging from mild side effects to life-
threatening, but rare, illnesses. In some cases, these reactions are caused by the vaccine; in 
others, they are caused by an error in the administration of the vaccine; and in the majority of 
cases, there is no relationship. Whatever the cause, when an adverse event following an 
immunization (AEFI) upsets people to the extent that they refuse further immunizations for their 
children, the children are much more likely to get a vaccine-preventable disease, become 
seriously ill, disabled, and even die. AEFI surveillance, therefore, helps to preserve public 
confidence in the immunization program. 
To increase immunization acceptance and improve the quality of services, the 
surveillance of severe AEFIs must become an integral part of immunization programs. In 
Response to a request by national program managers in 1990, the Expanded Program on 
Immunization (EPI) Global Advisory Group (GAG) of the World Health 
Organization (WHO) recommended that all immunization programs should be monitored. 
AEFIs and the WHO provide assistance in doing so. This guide was prepared in response. 
Each step in AEFI 
• Detection and reporting 
• Investigation 
• Data analysis 
• Corrective and other action 
• Evaluation 
Vaccines induce protection by eliciting active immune responses to specific antigens. 
There may be predictable adverse reactions (side effects): most are mild and resolve quickly. 
However, it is not always possible to predict individuals who might have a mild or serious 
reaction to a vaccine. The advice in this chapter uses the World Health Organization (WHO) 
classification of adverse events following immunization (AEFIs). It gives an overview of 
common side effects associated with vaccines and with the management of serious adverse 
reactions such as anaphylaxis. 
AEFIs may be true adverse reactions that are intrinsic to the vaccine, or may be caused 
by the way it is administered or be related to an underlying condition in the recipient. Other 
AEFIs may be coincidental and would have occurred regardless of vaccination. Adverse events 
following immunization can be local (e.g. Erythema, edema, pain) or systemic (e.g. Fever, 
exanthema, allergic reactions), and acute (within minutes of administration) or delayed (several 
hours or days after administration). Depending on the clinical relevance and severity, AEFI can 
be classified as physiological and nonphysiological. Physiological adverse events, reflecting 
natural reaction to the vaccine antigen, are common; they often include elevated body 
temperature, exanthema and myalgia, and usually have short duration. Since physiological 
reactions are believed to be natural, they are rarely reported. Non-physiological AEFI, 
sometimes referred to as hyper-reactions, are rare, unexpected and more severe than 
physiological AEFI, and they tend to occur in immunocompromised patients or patients allergic 
to vaccine components . 
Parents should be given advice about AEFIs that they can expect and how such events should be 
managed. The leaflets on vaccinations provided by the Department of Health give information about 
AEFIs and include advice on their management. Fevers over 37.5˚C are common in children and are 
usually mild. Advice on the use and appropriate dose of paracetamol or ibuprofen liquid to treat a fever 
should be given at the time of immunization. Guidance on the treatment of feverish illness in children less 
than five years of age from the National Institute for Health and Clinical Excellence can be found. Local 
reactions are usually self-limiting and do not require treatment. If they appear to cause discomfort, then 
paracetamol or ibuprofen can be given. Whilst paracetamol and ibuprofen can lower the duration of fever 
and reduce distress, there is no evidence that they prevent febrile convulsions. It is not therefore 
recommended that these drugs are used routinely to prevent fever following vaccination as there is some 
evidence that prophylactic administration of antipyretic drugs around the time of vaccination may lower 
antibody responses to some vaccines. 
Vaccination is one of the most cost-effective interventions to prevent major illnesses that 
contribute to child mortality in the country, particularly in environments where malnourished 
children, overcrowding, poverty and illiteracy reign. Knowledge (K), positive attitudes (A) and 
appropriate perceptions (P) about vaccination hence become one of the main tools to reduce the 
incidence of vaccine preventable diseases (VPDs) thus reducing childhood mortality and 
morbidity. In our society, a large chunk of the population lives in rural areas, where mothers are 
illiterate and have numerous myths about vaccination; this results in children being immunized 
and susceptible and hence causes a serious policy concern. Evidence about the inequalities in 
vaccination practices exist even though childhood immunization has been an important part of 
maternal and child health services since the 1940s.1 In 2010 it was estimated that 1.7 million 
children died from vaccine preventable diseases. It was also noted that 19.3 million children had 
been incompletely vaccinated, leaving them susceptible to vaccine preventable disease mortality 
and morbidity. Approximately 50% of all under vaccinated children live in three countries, India 
is one of them. 
The situation of under immunization is not only in the rural areas of the country, but also 
in urban areas as the migration of workers and the mushrooming of slums in urban areas are 
occurring at a rapid rate, and these are areas with unprecedented poverty, illiteracy, 
overcrowding and disease.4 National Family Health Survey-3 reports that only 43.5% of children 
in India receive all of their primary vaccines by 12 months of age.5 Main reasons identified for 
poor coverage includes inadequacy of community participation in routine immunization and 
Information Education and Communication activities.6 Negative parental perceptions of 
vaccination are also an important barrier to childhood vaccination. Therefore it is important to 
understand the variables that influence parental decisions to vaccinate their children and plan 
measures to overcome these barriers. A way to measure these variables, beliefs and behavior of 
parents is to conduct a Knowledge, Attitudes and Perceptions (KAP) study. With this outlook, 
this study was planned to assess the KAP of mothers with children less than five years of age 
about vaccination and to compare the KAP data between urban and rural setup.Soundarya 
Mahalingam.et.al.,(2014) 
Immunization is the most cost-effective and highest-impact health intervention which 
reduces hospitalization, treatment costs and mortality. Through the combined effort of WHO and 
UNICEF, and governments, the Expanded Program of Immunization was launched; and the 
proportion of the world’s children immunized against major vaccine-preventable diseases had 
increased from 20% in 1980 to over 80% in 1996—preventing more than 2.8M deaths in 
children, annually. Despite the success of EPI, many vaccine-preventable diseases have remained 
prevalent in developing countries (20% to 35% of all deaths in children under five). Vaccination 
efforts have doubled all over the world—following polio outbreaks in 18 countries since 2003, 
including in Nigeria and in neighboring Indonesia. Sylvia E.Caingles,et.al.,(2011) 
Immunization was greatly reduced the burden of infectious diseases. Immunization prevents 
illness, disability and death from vaccine-preventable diseases including diphtheria, measles, pertussis, 
pneumonia, polio, rotavirus diarrhea, rubella and tetanus. Parents’ knowledge about immunization and 
their attitudes towards them are likely influence uptake. Mothers’ knowledge about vaccination was found 
to be quite low and their educational status was significantly associated with the child’s coverage. Despite 
the fact that local and systemic reactions to vaccines are identified [9], but they were found to be one of 
the barriers to childhood immunization among other factors. Yousif MA,et.al., 
WHO classifies AEFIs according to four main categories? 
● Program related 
● Vaccine-induced  
● Coincidental  
● Unknown. 
Program-related AEFIs  
These are adverse events that result from inappropriate practices in the provision 
of vaccination. These may include:  
● Wrong dose of vaccine administered  
● Vaccines used beyond expiry date  
● Vaccines used at inappropriate intervals  
● Inappropriate route, site or technique of administration  
● Vaccine reconstituted with incorrect diluents  
● Wrong amount of diluents used  
● Vaccine prepared incorrectly  
● mixing into inappropriate combinations  
● Drugs substituted for vaccine or diluents  
● Vaccine or diluents contaminated  
● Vaccine or diluents stored incorrectly  
● Contraindications not elicited or ignored  
● reconstituted vaccine kept beyond the recommended period. 
Vaccine-induced AEFIs  
These are reactions in individuals specifically caused by a particular vaccine or its 
component parts. These may be induced, direct effects of the vaccine or one of its components, 
and/or due to an underlying medical condition or an idiosyncratic response in the recipient.  
Direct effects of vaccines include, for example, local reactions and fever within 48 hours 
of DTaP/IPV/Hib, rash and fever for seven to ten days after MMR, and parotitis three weeks 
after MMR.  
An example of an AEFI due to an underlying medical condition is vaccine associated 
paralysis which very rarely followed the use of live attenuated oral polio vaccine in a child with 
previously unrecognized severe combined immune deficiency.  
Idiosyncratic responses include idiopathic thrombocytopenic purpura (ITP) within 30 
days of MMR, and anaphylaxis immediately after vaccination. When there has been a confirmed 
anaphylactic reaction to a previous dose of the same vaccine, then this contraindicates further 
vaccinations with the same vaccine or a component of that vaccine.  
This category also includes medical conditions that would have occurred at some point in 
an individual, but are triggered earlier by the vaccination. This may include febrile seizures in a 
child with a family history of the same, or onset of infantile spasms (Bellman et al., 1983). 
Coincidental AEFIs  
These are not true adverse reactions to immunizations or vaccines, but are only linked 
because of the timing of their occurrence. When an AEFI is coincidental, the event would have 
occurred even if the individual had not been immunized. An example would be people who 
develop a cold with coryzal symptoms following flu vaccination. The flu vaccine does not 
prevent the common cold and colds are common in the winter when people are receiving the flu 
vaccine. 
Serious event 
An AEFI will be considered serious, if it: 
• Results in death, 
• Is life-threatening, 
• Requires inpatient hospitalization or prolongation of existing hospitalization, 
• Results in persistent or significant disability/incapacity, 
• Is a congenital anomaly/birth defect, or 
• Requires intervention to prevent permanent impairment or damage. 
Severe event 
Severe is used to describe the intensity of a specific event (as in mild, moderate or severe); the 
event itself, however, may be of relatively minor medical significance (e.g. Fever is a common, 
relatively minor medical event, but according to its severity it can be graded as mild fever or 
moderate fever). 
In this AEFI study there are both serious or events. this study contains only the severe 
events, there are no serious events. where severe events are classified into mild, moderate, and 
severe. This study contains only mild events like fever. There any other serious events are not 
presented. 
Some of the vaccine induced adverse events: 
.15 deaths were reported from Kerala from December 2011 –January 2013. A central team was 
formed (circular no T13020/11/2011-CCV dated 23rd Jan 2013)investigate the spate of serious 
AEFI cases (including death) from Kerala in Dec 2012. 
The team together with the members of the Kerala State AEFI committee then reviewed 
the cases in detail and classified them further based on the available investigation documents 
including the PIR and DIR of cases. This included review of cases reported with pentavalent 
vaccine and 2 other vaccines namely, Infanrix (DTaP, acellular pertussis in the DPT andnon-Hib 
containing vaccine) and Easy four(quadrivalent vaccine DPT+Hib). The discussion with the 
State AEFI committee members on reported AEFI deaths was put in context with the following 
background. 
1. Haemophilusinfluenzatype B is one of the leading causes of acute respiratory 
infection,pneumonia and meningitis in India and through govt. UIP program, it is made available 
to all strata of society free of cost. 
2. The vaccine has already been used in the private sector for more than a decade. 
3. Introduction of any new vaccine in the routine program is accompanied by an increased 
sensitivity of AEFI surveillance and hence increased reporting. (Example of Sri Lanka, where 
the vaccine was stopped due to increased AEFIs being reported and then restarted in the routine 
immunization program when the deaths were not found to be vaccinated-related) 
4. Introduction of pentavalent vaccine in the routine UIP program in Kerala too was 
accompanied by an awareness and capacity building activities of health workers, including 
structured training on AEFI reporting which also contributed to better AEFI reporting from the 
state. 
5. Profile of AEFIs expected with DPT vaccine is similar to that expected with the pentavalent 
vaccine due to the DPT+Hib+Heb B combination. 
6. Timely receipt of PIR (within 7 days of FIR) and DIR (within 90 days of FIR) at national level 
is of prime importance to aid any state AEFI investigation and enables better support to the state 
level from the national AEFI committee and AEFI surveillance program Agarwal:et.al.,(2013) 
A girl aged 4 months 6 days received second doses of diphtheria and tetanus toxoids and 
acellular pertussis vaccine (DTaP), inactivated polio vaccine (IPV), ha-mophilus influenzae type 
b (Hib) and conjugated pneumococcal vaccines in a primary care unit in 09.05.2012 they were 
performed according to the routine vaccination schedule of Ministry of Health. The baby 
received first doses on 09.03.2012 in the same unit. Her length was 62cm., body weight 6250 gr, 
head circumference: 41cm, body circumference: 43cm, arm circumference 15cm and no 
pathological symptoms were detected by physical examination On the same day 5 hours after 
injection, baby came with patch like several redness on her trunk. Similar skin lesions were 
detected on his face, back and chest re-gions. There was no dyspnea, wheezing, fever and any 
other abnormal signs. She had no history of food or drug allergy or previous adverse events after 
vaccinations. She did not have a history of asthma, food or drug intolerance. The baby was fed 
only with breast milk 
She was diagnosed with―Urticaria‖; an immediate systemic adverse reaction due to vaccination. 
She was treated with intramuscular prednisolone 1 mg/kg. Her symptoms completely resolved 
over the next 2 hours after the injection. Then the baby was sent to the secondary care unit. The 
next day family was invited to the polyclinic for control. There were no signs of urticaria on 
physical examination and all vital signs were normal. According to both timing and specific 
symptoms, it is consistent with an immediate type, IgE-mediated hypersensitivity reaction. It was 
decided that the reaction was an adverse reaction probably caused by vaccination. Skin testing 
would be indicated to elucidate the cause of the reaction before the administration of future 
doses. 
Discussion 
IPV vaccine is very safe and no serious vaccine adverse reaction was reported in Turkey. Similar 
adverse reactions related to Hib are rare. Local reactions (Pain, redness, and swelling) are most 
seen reactions. One of every 20 vaccinated (Hib) children, there would be fever over 38.8 ºC. 
Most seen adverse reaction due to DTaB are local and serious, life threatening reactions are 
infrequent. Especially using purified acellular DTaB instead of DTB decreased the incidence of 
symptoms like fever, fatigue and vomiting. Gluten allergy has also been shown to be the cause of 
allergic reactions with varicella, diphtheria-tetanus-acellular pertussis (DTaP)and Japanese 
encephalitis vaccines compared with the first dose; the fourth dose of currently licensed 
diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) has been associated with 
increased incidences of fever, erythema, swelling and pain at the injection site. In a small 
percentage of children, swelling of the entire thigh or upper arm for about four days has been 
reported after the fourth or fifth dose of DTaP. This self-limited reaction has been documented 
for multiple products from different manufacturers. After the4th or 5th booster dose or after a 
short injection interval (<5 to 10 years) with DTaP, local side effects (13) would be seen the 
local and serious systemic adverse reactions due to the vaccines were observed. 
Measles carry significant morbidity and mortality, and vaccination is the most effective 
means of prevention. Death occurs in 1 to 3 per 1000 cases of measles in the United States, with 
higher mortality in individuals younger than 5 years of age and among immunocompromised 
children. Among infants of vaccinated women, passive immunity wanes or disappears by the age 
of 6 months. As part of public health preparedness, characterizing the range of adverse events 
among young infants is crucial for understanding the safety profile of MMR vaccine. We 
focused on infants younger than 9 months of age because young infants are particularly 
vulnerable to wild-type infection and its complications and because adverse events following 
MMR combined vaccine or MMRV combined vaccine as opposed to the monovalent measles 
vaccine have not previously been described in this age group. 
In our review of VAERS, the vast majority of adverse events were nonserious, and many 
reports described a medication error without any adverse event per se. Fever and injection site 
reactions were among the most commonly reported events, as they are after routine vaccination 
at the age of 12–15 months. Because of the required incubation time of vaccine-strain viruses, 
the relevant window for MMR or MMRV-associated fever and febrile seizure is 5–12 days after 
vaccination. In our review, we identified only 4 cases of fever, including 1 febrile seizure, during 
that window. Our findings suggest that most fevers and febrile seizures in this series were not 
related to MMR or MMRV administration; alternative etiologies could include concurrent illness 
or concomitant vaccines, but the limitations of passive surveillance do not permit us to draw any 
definitive conclusions. We identified a small number of VAERS reports stating that MMRV had 
been administered to young infants, and all these adverse events were nonserious. MMRV is not 
indicated in infants younger than 12 months of age. 
In our analysis, 17% of adverse events met the regulatory definition of serious, which is 
consistent with the proportion of serious reports throughout VAERS. Nearly one-half of the 
serious reports were of international origin, but we believe that this high proportion relates to 
differential reporting requirements for manufacturers regarding US and foreign reports. We did 
not identify any unusual patterns of events, in particular body systems or clinical categories. A 
single death was attributed to SIDS. Epidemiologic analyses have not revealed a casual 
association between childhood immunizations and subsequent SIDS. Thrombocytopenia and 
transient arthralgiaare known to occur after MMR vaccination, but we did not receive any reports 
of these events among children younger than 9 months of age. Our review identified reports of 
Neurodevelopment disorders after MMR vaccination, including autism. However, epidemiologic 
analyses that were specifically designed to evaluate a possible relationship between vaccines and 
autism and other Neurodevelopment disorders strongly suggest that there is no causal link. In its 
review of the evidence and causality of adverse effects of vaccines, the Institute of Medicine 
concluded that the evidence favors rejection of a causal relationship between MMR vaccine and 
autism. 
Strengths of VAERS include its national scope, size, timeliness, ability to detect events 
that were not observed during prelicensure trials and surveillance among special populations. 
However, passive surveillance systems like VAERS are subject to many limitations, including 
underreporting, incomplete information, inadequate data regarding the numbers of doses 
administered, and lack of direct and unbiased comparison groups. Because of these and other 
limitations, it is usually not possible to verify causal associations between vaccines and adverse 
events from spontaneous reports to VAERS. Nevertheless, VAERS data have been used to 
describe a range of potential vaccine adverse events and to look for unexpected patterns in 
demographics and clinical characteristics that might lead to hypotheses that can be tested with 
epidemiologic studies. If widespread vaccination of infants has implemented in response to an 
outbreak, independent data from the FDA's Mini-Sentinel System or other sources may provide 
additional information about rates of adverse events among young infants given MMR vaccine. 
Recent media publications about measles and MMR vaccine have incorrectly stated or implied 
that children younger than 1 year of age cannot receive the vaccine. LK, Baker CJ, Kimerlin 
DW, et al.,(2015) 
In this study, we actively collected data on adverse events in a sample of pediatric GPs 
practices. The overall rate of AEFI after routine obligatory vaccination in children identified in 
our study was 209 per 100,000 vaccine doses, which is 6 times higher than the officia lly reported 
rate to the State Institute for Drug Control (an agency officially responsible for recording such 
events). The vast majority of AEFI were mild and local; the most common systemic AEFI was a 
fever; and only 16% required medical treatment. 
Several limitations of this study need to be considered when interpreting these results. 
First, although the practitioners were selected randomly, some 30% of invited GPs did not 
participate in the study. However, it is unlikely that non-participating practitioners had very 
different AEFI rates than those who participated in the study; the non-response therefore should 
not affect the results. 
The second potential limitation is the fact that data on AEFI are based on pediatric GP 
records, rather than on self-reported by the parents of children. It is likely that parents would 
report more adverse events than pediatricians; on the other hand, physicians are the only persons 
who are qualified to recognize the adverse event as a non-physiological. 
The third, and related, limitation is the question of what constitutes a non-physiological 
AEFI. Although national and WHO criteria exist, the distinction between physiological and non-
physiological adverse event is blurred, and the classification may depend on a number of factors, 
including GPs perceptions and the attitude of parents. The literature on AEFI rates is relatively 
sparse. Fritsche et al., using data from the US, the Netherlands and Australia, reported a very 
wide range of AEFI in these countries, between 4.8 and 83.0 per 100,000 doses of vaccines [3]. 
Surveillance of AEFI in Zhejiang province in China in 2008–2011 found 85 adverse events per 
100,000 infants under 1 year of age. As the data in these studies were collected using different 
methodology in each country, they cannot be directly compared; however, they do indicate the 
potential under-reporting of AEFI. 
The rate of AEFI in the present study (209 per 100,000 doses) was significantly higher 
than the rate reported to the State Institute for Drug Control (34 per100,000 doses), reflecting the 
difference between active surveillance used in our study and passive surveillance relying on 
reports to the national authority. On the other hand, the reports to the Czech State Institute for 
Drug Control included much higher proportion of serious AEFI than we found in our data. In our 
study, we included all adverse events that were available in pediatric GP records. We did not 
exclude any event. There were no AEFI described as pupae or GBS. In 2011, the Czech State 
Institute for Drug Control received a total of 817 AEFI reports, of which 51% were considered 
serious, compared with 3% seriousness AEFI in our study. Again, this is likely to reflect 
differences in data collection. In the study, we were focused on the collection of all AEFI 
described in GP offices. 
The Vaccine Adverse Event Reporting System (VAERS), maintained by the US Centre 
for Disease Control and Prevention and Food and Drug Administration, reported the rate of 
serious AEFI in 2006–2010 as 8%; this is not too far from the root seen in our study. Non-
serious AEFI are much more common; consistent with our study, local events (exanthema) were 
the most common symptoms reported after immunization in an analysis of the Chinese reporting 
system in 2009. 
Training of health care providers and education of the general public may improve the 
reporting of vaccine safety issues and gradually reduce the mistrust regarding vaccine safety 
harbored by some segments of the public.. In the Czech Republic, there are no detailed 
guidelines how AEFI should be reported, apart from the newsletter provided by the State 
Institute for Drug Control Vaccination registers, which currently exist in in 11 EU countries may 
be a possible solution but at present there are no plans to establish an immunization registry in 
the Czech Republic. Although the vast majority of AEFI identified in this study were mild. An 
establishment of a vaccination register, which would also collect data on AEFI, should be 
considered to improve the evidence on this important public health issue. The best way forward 
would be to have a vaccination registry with linkage available to other data at the GPs or 
hospitals to allow robust epidemiological studies to be done on vaccine safety signals (as WHO 
blueprint indicates) In addition, active surveillance of rare but serious events of interest (such as 
done by rapid cycle analysis in the Vaccine Safety Data link) would be useful. 
Jana Danova,et.al., 
Vaccinations in Infants and Children 
The vaccines that are recommended for routine immunization by the Centers for Disease Control 
and Prevention (CDC) in all children from birth through age 6 years are discussed below. For 
more detailed information, including exceptions and other considerations, see the CDC’s full 
vaccines and immunizations guidelines. 
The vaccines listed below are administered via intramuscular (IM) injection unless otherwise 
stated. IM administration in the anterolateral thigh muscle is preferred in neonates, infants, and 
small children. IM administration in the deltoid muscle is preferred in young children (e.g., aged 
4-6 years) who are of normal weight. 
Hepatitis B vaccine (HepB) 
 Minimum age: Birth 
 3 doses  
 First dose of monovalent HepB before hospital discharge*  
 Second dose with monovalent or combination vaccine at age 1 or 2 months  
 Third dose at age 6-18 months  
 *If mother is HBsAg-positive, also administer hepatitis B immunoglobulin (HBIG) 0.5 
ml within 12 hours of birth  
 *If mother’s HBsAg status is also unknown, administer HBIG to infants weighing < 2 kg 
within 12 hours of birth; determine the mother’s HBsAg status as soon as possible, and, if 
the mother is HBsAg-positive, also administer HBIG in infants weighing ≥2 kg as soon 
as possible, but not later than age 7 days  
Rotavirus vaccine (RV) 
 Minimum age: 6 weeks  
 2 or 3 doses administered orally 
 If  Rotarix is used, administer a 2-dose series at age 2 and 4 months  
 If  RotaTeq  is used, administer a 3-dose series at age 2, 4, and 6 months  
 If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the 
series, a total of 3 doses of RV vaccine should be administered  
Diphtheria, tetanus, acellular pertussis vaccine  (DTaP) 
 Minimum age: 6 weeks  
 Doses at ages 2 months, 4 months, 6 months, and 12-15 months  
 A final dose at age 4-6 years  
 If the fourth-dose DTaP vaccine was administered 4 months or more after the third dose, 
at an appropriate age, it can be counted as valid and need not be repeated after the 
recommended 6-month interval between doses 3 and 4. 
Haemophilus influenza type b vaccine  (Hib) 
 Minimum age: 6 weeks  
 2- or 3-dose primary series and 1 booster dose (dose 3 or 4 depending on vaccine used for 
primary series) at age 12-15 months  
 Doses at ages 2 months, 4 months, 6 months (brand dependent), and booster at 12-15 
months  
Pneumococcal vaccine 13-valent (PCV13) 
 Minimum age: 6 weeks  
 Doses at ages 2 months, 4 months, 6 months, and 12-15 months  
 See the CDC’s full vaccines and immunizations guidelines for updated (2015) scheduling 
considerations. 
In 2015, the Advisory Committee on Immunization Practices provided recommendations on the 
pneumococcal polysaccharide vaccine (PPSV23) and the pneumococcal conjugate vaccine 
(PCV13), summarized as follows: 
 The ACIP currently recommends that a dose of PCV13 be followed by a dose of PPSV23 
in persons aged 2 years or older who are at high risk for pneumococcal disease because of 
underlying medical conditions.  
 Children with an immune compromising condition or functional or anatomic asplenia 
should receive a second dose of PPSV23 5 years after the first PPSV23 dose.  
 
Inactivated poliovirus vaccine  (IPV) 
 Minimum age: 6 weeks  
 4 doses administered IM (may administer SC or IM in depleted in older children)  
 Doses at ages 2 months, 4 months, 6-18 months, and age 4-6 years  
Influenza vaccine 
 Minimum age: 6 months for trivalent inactivated vaccine(TIV) and the quadrivalent 
inactivated vaccine (brand dependent); 2 years for live attenuated vaccine (LAIV) (see 
the CDC’s full vaccines and immunizations guidelines for updated [2015] LAIV 
contraindications/considerations) 
 Children aged 6 months to 8 years who are receiving their first influenza vaccination 
should receive 2 doses (separated by at least 4 weeks) and then 1 dose in subsequent 
years  
Guidelines on immunization from the American Academy of Pediatrics Committee on Infectious 
Diseases and the Advisory Committee on Immunization Practices specify that the live attenuated 
influenza vaccine (LAIV) should not be administered to some persons, including the following: 
 Persons who have experienced severe allergic reactions to LAIV, any of its components, 
or a previous dose of any other influenza vaccine  
 Children aged 2-17 years, receiving aspirin or aspirin-containing products  
 Persons who are allergic to eggs  
 Pregnant women  
 Immunosuppressed persons  
 Children aged 2-4 years with asthma or who have had wheezing in the past 12 months  
 Persons who have taken influenza antiviral medications in the previous 48 hours  
Measles, mumps, and rubella vaccine  (MMR) 
 Minimum age: 12 months  
 Administer by SC into the outer aspect of the arm  
 Two dose series at ages 12-15 months and 4-6 years  
Varicella virus vaccine 
 Minimum age: 12 months  
 Administer by SC injection into the outer aspect of the upper arm or the anterolateral 
thigh  
 Two-dose series at ages 12-15 months and 4-6 years  
Hepatitis A vaccine (HepA) 
 Minimum age: 12 months  
 Two-dose series beginning at ages 12-23 months; the second dose is given 6-18 months 
later  
The following clinical practice guidelines were released in 2015 by Help Eliminate Pain in Kids 
 No aspiration should be used during intramuscular vaccine injections in individuals of all 
ages.  
 Inject the most painful vaccine last (rather than first) during vaccine injections in 
individuals of all ages.  
 Breast feeding should be used during vaccine injections in children aged 2 years and 
younger.  
 Holding should be used (rather than the child lying supine) during vaccine injections in 
children aged 3 years and younger.  
 Sitting upright should be used (rather than the individual lying supine) during vaccine 
injections in children aged 3 years and older and adults.  
 Apply topical anesthetics before vaccine injections in children aged 12 years and 
younger.  
 Give sucrose solution before vaccine injections in children aged 2 years and younger.  
 Educate parents about pain management before the day of vaccination and on the day of 
vaccination.  
 Educate children aged 3 years and older about pain management on the day of 
vaccination.  
 Parents should be present during vaccine injections in children aged 10 years and 
younger. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LITERATURE REVIEW 
 
Adriana Parrella Annette Braunack-Mayer,Michael Gold,Helen Marshall and 
Peter Baghurstet.al.,  Healthcare providers’ knowledge, experience and challenges of reporting 
adverse events following immunisation: a qualitative study described as they concluded This 
study provides an overview of experience and beliefs of three healthcare professional groups in 
relation to identifying and reporting AEFI. The qualitative assessment reveals differences in 
experience and awareness of AEFI reporting across the three professional groups. Most 
participants appreciated the importance of their role in AEFI surveillance and monitoring the 
ongoing safety of vaccines. Future initiatives to improve education, such as increased training to 
health care providers, particularly, medical professionals, are required and should be included in 
both undergraduate curricula and ongoing, professional development. 
 
F. M. Turnbull et al., describes in his study ofthe National Study of Adverse Reactions after 
Vaccination with Bacille Calmette-Gue´rin in a prospective national study Local reactions 
were more frequently reported by adult females than by adult males (RR, 7.18; 95% CI, 1.59–
32.45). Adverse reactions were not significantly associated with any currently available vaccine 
batch, previous receipt of BCG vaccine, or concomitant administration of other vaccines. 
 
Jana Danovaet.al., described the studyActive surveillance study of adverse events following 
immunization of children The rate of AEFI identified in this study was considerably higher 
than the officially reported rate. Although the vast majority of AEFI were non-serious, health 
care providers and the public should be educated and encouraged to report AEFI to address the 
issue of underreporting, to increase the safety profile of vaccines, and to improve public 
confidence in immunizationprograms. 
 
J. Kurian,et.al., Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective 
Observational Study as described the concluded asAmong the pediatric population, infants, male 
gender and those receiving ≥4 number of medications are at risk of developing ADRs. Constant 
monitoring is required to address the safety issue in pediatric population, especially in infants 
and patients receiving ≥4 drugs. 
 
Katrin S. Kohl,1 S. Michael Marcy et.al., described the study on Fever after Immunization: 
Current Concepts and Improved Future Scientific Understanding In conclusion, although 
many aspects of the society, medical, economic, and epidemiologic meaning of fever as an AEFI 
are still elusive, it is a common, generally benign, clinical sign. We consider the cost of a 
potentially unnecessary clinical/diagnostic evaluation of a child with fever after immunization to 
be clearly offset by the risk of complications of disease that would result had we no vaccination 
programs. In addition, a globally standardized assessment and reporting of the event, as proposed 
by the Brighton Collaboration, is a step toward a more rigorous scientific understanding of its 
incidence and true significance. 
 
Muchekeza M, et al., conducted studies on Adverse Events Following Immunization (AEFI) 
Surveillance in Kwekwe District Lack of knowledge of AEFI surveillance procedures was the 
main challenge. As a result, 150 (45%) nurses were trained in AEFI surveillance and surveillance 
forms were distributed to all health facilities. 
 
PATJA, ANNAMARI MD; et.al.,described the studySerious adverse events after measles-
mumps-rubella vaccination during a fourteen-year prospective follow-upCausality between 
immunization and a subsequent untoward event cannot be estimated solely on the basis of a 
temporal relation. Comprehensive analysis of the reported adverse reactions established that 
serious events causally related to MMR vaccine are rare and greatly outweighed by the risks of 
natural MMR diseases 
 
REPORT OF CENTRAL TEAM FOR ASSISTANCE IN INVESTIGATION OF 
SERIOUS AEFI CASES IN KERALA (4th-6th Feb 2013) the team has concluded in the 
study was state officials and the field visits undertaken the team gave the following 
recommendations specifically for these cases and in the long term for improved AEFI 
surveillance in immediate and long term events. 
 
Salman Khazaei, et.al., described the study onAdverse Events Following Immunization 
(AEFI) in Children under 7- year of Age during 2014 in Hamedan Province, Iran Our study 
shown, an increased risk of AEFI in the region and point out that the programmatic error still 
needs to be considered. Accordingly, the more activities need to be consolidated to reduce the 
adverse effect. This study assessed the different aspects of AEFI which may help policy makers 
to improve the immunization programs. 
 
Soundarya Mahalingam1 , Abhijna Soori2, Pradhum Ram2, Basavaprabhu Achappa3, Mukta 
Chowta4 , Deepak Madi3 2014 described the study on Knowledge, attitude and perceptions of 
mothers with children under five years of age about vaccination in Mangalore, India its 
concluded A significant number of mothers in rural areas were unaware about the vaccination 
and its implications. Even in the urban areas we found significant lacunae in the KAP of mothers 
towards childhood vaccination.  
 
Sylvia E. Caingles, MD*, Joanne J. Lobo, M. D*2011  described the study onSurvey on the 
knowledge, attitudes and practices of parents in barangay 8A, district, Davao city regarding their 
children's immunization its concluded Parents still lacked knowledge with regards to their 
children’s vaccination. The outcome of the child being fully immunized depends on the 
availability and affordability of vaccine, as well as, the willingness and effort of their parents. 
 
W. Katherine Yih, PhD, MPH. et.al, conducted study Active Surveillance for Adverse 
Events: The Experience of the Vaccine Safety Data link Project Care with data quality, 
outcome definitions, comparison groups, and length of surveillance are required to enable 
detection of true safety problems while minimizing false signals. Some causes of false signals in 
the VSD system were preventable and have been corrected, whereas others will be unavoidable 
in any active surveillance system. Temple scan statistics, analyses to control for confounding, 
and chart review are indispensable tools in signal investigation. The VSD’s experience may 
inform new systems for active safety surveillance. Pediatrics 2011; 127:S54–S64. 
 
Wagon Zhou, M.D., Ph.D.et.al,conducted the study onSurveillance for Safety After 
Immunization: Vaccine Adverse Event Reporting System (VAERS) --- United States, 
1991—2001During 1991--2001, VAERS received 128 717 reports, whereas >1,9 billion net 
doses of human vaccines were distributed. The overall dose-based reporting rate for the 27 
frequently reported vaccine types was 11,4 reports per 100 000 net doses distributed. The 
proportions of reports in the age groups <1 year, 1--6 years, 7--17 years, 18--64 years, and >65 
years were 18,1 %, 26,7 %, 8 %, 32,6 %, and 4,9 %, respectively. In all of the adult age groups, 
predominance among the number of women reporting was observed, but the difference in sex 
was minimal among children. Overall, the most commonly reported adverse event was fever, 
which appeared in 25,8 % of all reports, followed by injection-site hypersensitivity (15,8 %), 
rash (unspecified) (11 %), injection-site edema (10,8 %), and vasodilatation (10,8 %). A total of 
14, 2 % of all reports described serious adverse events, which by regulatory definition include 
death, life-threatening illness, hospitalization or prolongation of hospitalization, or permanent 
disability. Examples of the uses of VAERS data for vaccine safety surveillance are included in 
this report. 
 
 
 
 
YU Ye-bin, HUANG Ke et.al.,Analysis of surveillance data for adverse events following 
immunization during year 2006-2011 in Yangchunconducted the study onduringthe year 
2006-2011 AEFI incidence in Yangchun was within the reported range under the national pilot 
estimation. There is a need to standardize immunization work, improve the quality of vaccination 
and strengthen AEFI surveillance, so as to reduce the occurrence of adverse events after 
vaccination and improve AEFI surveillance sensitivity. 
 
Yousif MA, et al.,Ahmed Abdulrahman Albarraq, Mustafa Awad A Abdallah and Abubaker 
Ibrahim Elbur* described the study on Parents′ Knowledge and Attitudes on Childhood 
Immunization, Taif, Saudi Arabia and its concluded the study on Although parents had good 
knowledge and positive attitudes on some aspects related childhood immunization, gaps in both 
studied domains were identified. Educational interventions are needed to upgrade parents’ 
knowledge with special emphasis on less educated and residents of rural areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIM AND OBJECTIVES 
AIM:  
                 To identify the adverse event following immunization and its management in the 
Pediatric Population. 
 
  
OBJECTIVES: 
 
Primary objective: 
 
 Classify the observed adverse event and its management 
 Incidence of adverse event after vaccination. 
 Type of reaction for different adverse event. 
 
Secondary objective: 
 
 Knowledge about the immunization in parents. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
5. PLAN OF STUDY 
The study was planned with four different phases: 
PHASE I: 
 Preliminary literature survey  
PHASE II: 
 Obtaining approval from ethical committee 
 Literature survey 
PHASE III: 
 Data collection 
 Data collection form 
 Data analysis 
PHASE IV: 
 Results and discussion. 
 
 
 
 
 
 
 
  
 
     6. METHODOLOGY 
 STUDY TYPE   
Prospective observational study.  
 STUDYSITE   
The study was carried out in PSG hospital, Department of Pediatrics. 
 STUDY DURATION   
October 2016 to April 2017 
 INCLUSION CRITERIA: 
Both male and female children are in birth to 5 years. 
Those who are willing to participate in the study 
Patients those who will be available during the study 
Children undergoing vaccination according WHO guidelines. 
 
 EXCLUSION CRITERIA: 
More than 5 years 
Birth deformity children. 
 SAMPLE SIZE: 
183 patients 
 STUDY TOOLS: 
Patient data collection form 
Knowledge questionnaire 
 DATA COLLECTION: 
A prospective observational study was carried out on childrens in the Paediatrics 
Outpatient, Department of PSGIMS&R, COIMBATORE. 
  STUDY APPROVAL:  
The approval for the study was obtained from the Institutional Human Ethical Committee (IHEC), 
PSGIMS&R,CoimbatoreProject no: 16/336  
METHODOLOGY: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial screening  Exclusion criteria 
More than 5 years 
Birth deformity children’s. 
 
 Inclusion criteria 
Both male and female childrens in birth to 5 years. 
Those who are willing to participate in the study 
Patients those who will be available during study 
Children undergoing vaccination according WHO guidelines 
Basic demographic data and 
follow up 
Knowledge questionnaire 
 
Observe AEFI and management 
Results and conclusion 
Report to pharmacovigilance 
RESULTS 
ACCORDING TO GENDER 
Out of 183 patients, 42 % (n=76) were male children and 58 % (n=107) were female childrens as 
shown in Table 1 and Fig 1. 
 
 
 
Table-1:  Percentage distribution of patients, according to gender 
 
 
Figure-1: Pie Chart showing the percentage distribution of patients, according to gender 
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107, 58% 
Gender ratio 
MALE FEMALE 
GENDER TOTAL PERCENTAGE 
Male 76 42% 
Female 107 58% 
TOTAL 183 100% 
ACCORDING TO AGE SECTOR 
Out of 183 patients, 34% (n=63) patients belong to age sector 0-6 month and 17% (n=31) of 
patients belongs to 6-12 month and 34% (n=62) of patients belongs to 1-3 year and 15% (n=27) 
of patients belongs to 3-5year  as shown in Table 2 and Fig 2. 
 
 
 
 
Table-2: Percentage distribution of patients, according to age 
 
 
 
Figure-2: Bar diagram showing the percentage distribution according to age 
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AGE TOTAL PERCENTAGE 
0-6months 63 34% 
6-12months 31 17% 
1-3years 62 34% 
3-5years 27 15% 
TOTAL 183 100% 
ACCORDING TO PERCENTAGE OF AEFI 
Out of 183 patients 18% (n=33) of children were developed AEFI and 60% (n=110)of the 
children were normal shown in Table 3 and Figure 3. 
CATEGORY TOTAL PERCENTAGE 
AEFI 33 18% 
NORMAL 110 60% 
NO RESPONSE 40 22% 
TOTAL 183 100% 
 
Table-3: Percentage distribution of patients, according to AEFI 
 
Figure-3: Pie Chart showing the percentage distribution of patients, according to AEFI 
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ACCORDING TO MONTH WISE POPULATION 
Out of 183 patients, according to month wise population, 19% of the population were vaccinated in 
November month and 21% of the population were vaccinated in December month and 22% of the 
population were vaccinated in January month and 23% if patients were vaccinated in February month and 
finally 15% of patients only were vaccinated in march month shown in Table 4 and Figure 4. 
MONTH VACCINE 
POPULATION 
PERCENTAGE 
NOVEMBER 35 19% 
DECEMBER 38 21% 
JANUARY 40 22% 
FEBRUARY 42 23% 
MARCH 28 15% 
TOTAL 183 100% 
 
Table-4: Percentage distribution of patients, according to month wise vaccine 
Population 
 
Figure-4: Bar diagram showing the percentage distribution according to month wise 
vaccine Population 
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ACCORDING TO VACCINE WISE POPULATION 
Out of 183 patients 19% of the population are vaccinated Hep B is shown in Table 5 and Figure 5.  
VACCINE POPULATION PERCENTAGE 
HEPATITITS B 35 19% 
POLIO 25 14% 
DTP 28 15% 
Hib type b 22 12% 
ROTAVIRUS 12 7% 
MEASLES 03 2% 
RUBELLA 09 5% 
Hepatitis A 16 9% 
MUMPS 12 7% 
VARICELLA 18 10% 
TOTAL 183 100% 
 
Table-5: Percentage distribution of patients, according to vaccine wise population. 
 
Figure-5: Bar diagram showing the percentage distribution according to vaccine wise 
population 
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ACCORDING TO AEFI IN FEVER  
Out of 183 patients in the study, and the 33 patients having fever as an adverse event. The 58% (n=19) of 
female children having fever and 42% (n=19) of male children having fever shown in Table 6 and Figure 
6  
GENDER POPULATION 
(fever) 
PERCENTAGE 
MALE 14 42% 
FEMALE 19 58% 
TOTAL 33 100% 
 
Table-6: Percentage distribution of patients, according to AEFI. 
 
 
 
Figure-6 Pie Chart showing the percentage distribution according to AEFI (fever) 
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RESULTS FOR KNOWLEDGE OF THE PARENTS ABOUT VACCINATION 
PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-1 
1. Do you think vaccine is important? 
Out of 183 parents, 77% (n=140) of parents are saying yes, vaccines are important and 18% (n=33) of 
parents said don’t know, only 5% (n=10) of parents said it was not important shown in Table 7 and Figure 
7 
Question 1 Population Percentage 
Yes 140 77% 
No 10 5% 
Don’t know 33 18% 
Total 183 100% 
 
Table 7: Percentage distribution of population knowledge about  question 1 
 
 
Figure 7: Pie Chart showing the percentage distribution of population knowledge about 
question 1 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-2 
Is it important to follow the vaccination schedule? 
The 67% of parent population told that the vaccination schedule was important and 15%of 
parents said it was not important shown in Table 8 and Figure 8. 
Question 2 Population Percentage 
Yes 123 67% 
No 27 15% 
Don’t know 33 18% 
Total 183 100% 
 
Table 8: Percentage distribution of population knowledge about  question2 
 
Figure 8: Pie Chart showing the percentage distribution of population knowledge about 
question 8 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION 
What is the maximum age of vaccines can be administered? 
Out of 183 parents, 53% (n=98) of parents were answered the vaccination is 5 years and 32% (n=58) of 
parents are saying 10 years and 15% (n=27) parents are saying adults shown in Table 9 and Figure 9. 
 
 
Table 9: Percentage distribution of population knowledge about  question3 
 
 
Figure 9:Pie Chart showing the percentage distribution of population knowledge about 
question 3 
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Question 3 Population Percentage 
5 years 98 53% 
10 years 58 32% 
Adults 27 15% 
Total 183 100% 
PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-4 
Would you vaccinate with fever? 
Out of 183 parents,32 %( n=59) of parents were ready to vaccinate with fever, major parent 
population was not agreed to vaccinate with fever shown in Table 10 Figure 10. 
Question 4 Population Percentage 
Yes 59 32% 
No 124 68% 
Total 183 100% 
 
Table 10: Percentage distribution of population knowledge about  question4 
 
 
 
Figure 10:Pie Chart showing the percentage distribution of population knowledge about 
question 4 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-5 
Would you vaccinate in summer? 
Out of 183 parents, 46% (n=85) of parents were ready to vaccinate in summer, and 30% (n=55) of parents 
are not agreeing to vaccinate in summer and minor percentage of  the population are said don’t know 
shown in Table 11 and Figure 11. 
Question 5 Population Percentage 
Yes 85 46% 
No 55 30% 
Don’t know 43 24% 
Total 183 100% 
 
Table 11: Percentage distribution of population knowledge about  question 5 
 
 
Figure 11: Pie Chart showing the percentage distribution of population knowledge about 
question 5 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-6 
Would you vaccinate with cold? 
Out of 183 parents, 22% (n=41) of parents were ready to vaccinate with cold, major parent population 
was not agreed to vaccinate with cold  shown in Table 12 Figure 12. 
Question 6 Population Percentage 
Yes 41 22% 
No 142 78% 
Total 183 100% 
 
Table 12: Percentage distribution of population knowledge about  question6 
 
 
Figure 12: Pie Chart showing the percentage distribution of population knowledge about 
question 6 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-7 
Will side effect appear after vaccination? 
Out of 183 parents, 18% (n=33) of parents were told after vaccination side effect will appear and 60% 
(n=110) of parents were telling side effect was not appearing shown in Table 13 and Figure 13. 
Question 7 Population Percentage 
Yes 33 18% 
No 110 60% 
Don’t know 40 22% 
Total 183 100% 
 
Table 13. Percentage distribution of population knowledge about  question7 
 
 
 
Figure 13:Pie Chart showing the percentage distribution of population knowledge about 
question 7 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-8 
Will you inform the doctor/health care worker about the side effect seen in your child? 
If  they identify any side effects will inform 71%(n=130) of parents told and 13%(n=23) of parents are 
saying will not inform doctors or any other health care workers shown in Table 14 and Figure 14. 
Question 8 Population Percentage 
Yes 130 71% 
No 23 13% 
Don’t know 30 16% 
Total 183 100% 
 
Table 14: percentage distribution of population knowledge about  question8 
 
 
Figure 14:Pie Chart showing the percentage distribution of population knowledge about 
question 8 
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Whether vaccines are harmful? 
The 17% (n=31) of parents were filled yes and 45% (n=85) of parents filled no and the 38% (n=70) of 
parents were filled don’t known shown in Table 15 and Figure 15. 
Question 9 Population Percentage 
Yes 31 17% 
No 82 45% 
Don’t know 70 38% 
Total 183 100% 
 
Table 15: Percentage distribution of population knowledge about  question9 
 
Figure 15: Pie Chart showing the percentage distribution of population knowledge about 
question 9 
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PERCENTAGE OF POPULATION KNOWLEDGE ABOUT QUESTION-10 
Till now whether immunization was completed as per the WHO schedule for your children? 
The 73% (n=133) of parents were going as per the WHO immunization schedule and 27% (n=50) of 
parents were represented they don’t know about schedule vaccination shown in Table 16 and Figure 16.  
Question 10 Population Percentage 
Yes 133 73% 
No 50 27% 
Total 183 100% 
 
Table 16:Percentage distribution of population knowledge about  question 16 
 
 
 
Figure 16:Pie Chart showing the percentage distribution of population knowledge about 
question 10 
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 Answered for the question where did you look the immunization vaccines: 
Out of 183 parents are 18% (n=33) of parents are looking in the internet and 25% (n=45) of parents are 
looking in clinics and 15% (n=28) of parents are looking in media and 25% (n=45) of parents are looking 
in a magazines and 17% (n=32) of parents are asking neighbors shown in table 11 and figure 11. 
 Population Percentage 
Internet 33 18% 
Clinics 45 25% 
Media 28 15% 
Magazine 45 25% 
Neighbours 32 17% 
Total 183 100% 
 
Table 17: Percentage distribution of population where did you look the immunization 
vaccines 
 
Figure-17: Bar diagram showing the percentage distribution of population where did you 
look the immunization vaccines? 
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DISCUSSION 
 
In this study, we actively collected data on adverse events in a sample of pediatric GPs 
practices. The majority of the AEFI cases were either mild or moderate in severity.  Common 
reported reactions include fever. Identification of AEFI enables the improvement of health care 
routines for children and contributes to interventions aiming at the safety of vaccines as the 
passive surveillance of AEFI may be considered useful in the monitoring of vaccine-related 
safety. 
 
A potential limitation is that fact the data on AEFI are based on pediatric GP records, rather than  
Oneself-reported by the parents of children. It is likely that parents would report more adverse 
 Events than pediatricians on the other hand, physicians are the only persons who are qualified  
to recognize the adverse event as a non-physiological. 
 
Studies have been done in different parts of the world on ADRs among pediatric patients. It has 
been found that ADRs were associated with 209 reported deaths among young children each 
year, in the age groups of newborn to 2 years of age. Similarly, in our present study, nearly 60% 
of the ADRs occurred in patients less than 1 year of age. A case of death had also been reported 
during the 2 month study period.Danova et al. BMC Public Health (2017) 17:167 
 
Specific measures to prevent AEFI, including proper screening to verify possible 
contraindications or the need to postpone vaccines, continuous training for vaccinations, and 
education in health may contribute to the quality and safety of immunization, thus ensuring the 
advances verified in the eradication and control of diseases preventable by immunization. It is 
important to mention that the evidence on the safety and effectiveness of vaccines in the routine 
of immunization in children and adults are significantly favorable. 
 
Here in this study Out of 183 patients, 42 % (n=76) were male and 58 % (n=107) were 
female, were female patients are showing a high prevalence compared to male.  This shows that 
the female were being born more than the male child. This differed with most studies and could 
be explained by the distribution variation 
 
 
According to age sector among the 183 children,0-6 month is a high percentage (34%) of  birth 
and according to percentage of AEFIamongst the patients who underwent the study, 18% had an 
AEFI which showed up as fever, 60% were normal and 22% of the patients did not response  
attending the phone call during followup. 
According to vaccine wise population, the most common vaccination undertaken in this 
study was Hepatitis B which had 19% undertake. DTP, Polio and Hib also had a high prevalence 
in this study. Treatment guidelines have also shown that the main four vaccines children received 
are: 
 A. Hep B- protects against hepatitis B (infection of the liver). HepB is given in three 
shots. The first shot is given at the time of birth. Most states require HepB vaccination for a child 
to enter school. 
B. RV protects against rotavirus, a major cause of diarrhea. The RV is given in two or 
three doses, depending on the vaccine used. 
C. DTaP protects against diphtheria, tetanus, and pertussis (whooping cough). It requires 
five doses during infancy and childhood. DTaP boosters are then given during 
adolescence and adulthood. 
D. Hib protects against Haemophilusinfluenzae type b. This infection used to be a leading 
cause of bacterial meningitis. Hib vaccination is given in four doses. 
The common AEFIS include mild, moderate or severe fever, local erythema, irritability, 
drowsiness, rash, cough , nausea and vomiting and diarrhea among others. 
Discussion on Knowledge questionnaire’s which was conducted among the  parents,  
 
Analysis of the demographic characteristics of the parents participated in the present study 
showed that the mothers constituted the majority of the sample. Understanding the mothers’ 
knowledge and attitudes towards immunization is important, although the father’s 
involvement was shown to be associated with the child’s vaccinationstatus.Yousif et al., J 
Vaccines Vaccine (2013, 5:1). More than half of the parents had higher education. This may be 
explained by the fact that the majority of the participants were living in the town where they 
were originally born and had better chances to complete their higher education. Assessment of 
the parents’ knowledge in the current study showed variations in responses to questions designed 
to assess their knowledge on childhood immunization. The majority of them knew that routine 
vaccination prevents children from some serious infectious diseases and its complication. 
A study conducted in UAE more than 85% of the participants knew the role of childhood 
vaccination in prevention of life-threatening diseases. 
 
Current recommendation in USA is to vaccinate all children from6 months up to 19 years – with 
particular emphasis on children under the age of 5 year or with chronic illnesses with Influenza 
vaccines. According to our results 70% of parents are well knowledged. 
 
In this study the majority of parent population had fair knowledge regarding vaccination. still 
some lacunae was observed in the remaining study population. This lacunae should be addressed 
by the health care professionals during the immunization visit. 
 
In present study physician clinic and magazine are a main source of information regarding 
immunization accounting to 25% followed by internet. 
 
The parent population reported that during fever they won’t administered vaccination at 
cold.Thesemust be abolished and mothers must be assured regarding the safety of vaccines. 
60% of study population not addressing the side effects in their children following vaccination. 
 
Still the parents concern with the children they are ready to inform if any of the side effects seen 
in their children. Mothers were more aware and showed favorable attitude regarding side effects. 
 
The study found that 73% of parent were the vaccination coverage, 27% of parent were missed 
one (or) two vaccination. Hence steps to be taken to ensure good education about vaccination 
coverage and the goals of eradication of disease like polio may be achieved. 
 
 
 
 
 
CONCLUSION 
According to our study, 60% of patients are not affected by any adverse effect and only 
18% of patients having the adverse event. The majority of adverse events are in female children. 
In the view of AEFI, immunization process  was very perfect and does not produce  any 
problems, so based on our study  pediatric vaccines are very safety for children under the age of 
five years. 
This study has been concluded that 70% of parents are well knowledge about immunization 
vaccines and some of the parents are only unknown. 
Health care workers and other professionals are spontaneous to report the AEFI report  to 
improve the reducing side effects in there serious death also. 
This study demonstrates that the people should concern about risks and knowledge about 
immunization, all healthcare providers and the general public should be educated about AEFI 
report. Health care providers should be encouraged to report AEFI report to address the issue, to 
increase the safety profile of vaccines, and to improve public confidence in immunization 
programs. 
Vaccine awareness should be enhanced through the use of mass media like television, radio and 
newspaper, as these were observed to be underutilized in this study. Government must include 
these newer vaccines in the national immunization program in a phase wise manner. 
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